AAO-HNSF, AHNS Sponsor Thyroid Cancer Research
Paul M. Weinberger, MD Medical College of GeorgiaThe incidence of thyroid cancer is increasing at an alarming rate, with an estimated 48,000 new thyroid cancer diagnoses expected in 2011. Although most thyroid cancers are found during evaluation of a thyroid nodule, only 5 percent of thyroid nodules are malignant. Currently, most thyroid nodules are evaluated by histological analysis of fine needle aspirates (FNA). Depending on collection technique, up to 20 percent of FNAs can be inconclusive; most such patients will undergo surgical resection of part of the thyroid. Three-fourths of these cases then prove benign on final histological examination, but the patient had to undergo a surgical procedure to make that determination. Biomarkers that could discriminate between benign and malignant are therefore desperately needed to help in the management of patients with nodular thyroid disease. In 2011, the AAO-HNSF and the American Head and Neck Society (AHNS) co-sponsored a Young Investigator Grant for $40,000. The grant was awarded through the Centralized Otolaryngology Research Efforts (CORE) grant program and awarded to Paul M. Weinberger, MD, at Georgia Health Sciences University in Augusta, GA, for his project titled “Minimally Invasive Multiplexed Assays for the Detection of Thyroid Cancer.” Much research has already been done in this area. So far, an adequate biomarker-based test has not been identified. It has been proposed that a panel of biomarkers may instead represent the best approach. Dr. Weinberger’s preliminary data show real promise for a combination of two biomarkers Galectin-3 and HBME-1. He will apply two proteomics techniques multiple reaction monitoring (MRM) and Luminex, for the detection of these biomarkers in complex biological fluids. Preliminary studies have shown that MRM has exquisite sensitivity, detecting as little as 100 attomoles of Galectin-3 in a patient sample (similar in scale to detecting a single grain of salt dissolved in a swimming pool). Using this novel approach, Dr. Weinberger and his team hypothesize that detection of these biomarkers by MRM or Luminex will allow minimally invasive detection of Papillary Thyroid Carcinoma from thyroid FNA needle washings and serum. By the end of the study, they hope to have an assay ready for testing in the clinical setting, able to distinguish the 95 percent non-cancerous thyroid nodules from the 5 percent that actually harbor thyroid cancer. This will hopefully translate in the long run into fewer surgeries performed for diagnosis, and improved patient outcomes.
In 2011, the AAO-HNSF and the American Head and Neck Society (AHNS) co-sponsored a Young Investigator Grant for $40,000. The grant was awarded through the Centralized Otolaryngology Research Efforts (CORE) grant program and awarded to Paul M. Weinberger, MD, at Georgia Health Sciences University in Augusta, GA, for his project titled “Minimally Invasive Multiplexed Assays for the Detection of Thyroid Cancer.”
Much research has already been done in this area. So far, an adequate biomarker-based test has not been identified. It has been proposed that a panel of biomarkers may instead represent the best approach. Dr. Weinberger’s preliminary data show real promise for a combination of two biomarkers Galectin-3 and HBME-1. He will apply two proteomics techniques multiple reaction monitoring (MRM) and Luminex, for the detection of these biomarkers in complex biological fluids.
Preliminary studies have shown that MRM has exquisite sensitivity, detecting as little as 100 attomoles of Galectin-3 in a patient sample (similar in scale to detecting a single grain of salt dissolved in a swimming pool). Using this novel approach, Dr. Weinberger and his team hypothesize that detection of these biomarkers by MRM or Luminex will allow minimally invasive detection of Papillary Thyroid Carcinoma from thyroid FNA needle washings and serum.
By the end of the study, they hope to have an assay ready for testing in the clinical setting, able to distinguish the 95 percent non-cancerous thyroid nodules from the 5 percent that actually harbor thyroid cancer. This will hopefully translate in the long run into fewer surgeries performed for diagnosis, and improved patient outcomes.